Furthermore, compared to general population, no increased risk for T1DM patients (IRR = 0.31, 95% CI 0.08, 1.24) or for T2DM insulin users (IRR = 0.90, 95% CI 0.64, 1.28) was observed in the group of miscellanea cancer sites (Supplementary Material Table S4). This evidence concerns the gene INS and cancer.